X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards, approved by X4's Compensation Committee, consist of options to purchase 744,468 shares of X4's common stock. These options have a ten-year term and an exercise price of $0.6693 per share, equal to the closing price on September 30, 2024.
The options will vest over a four-year period, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, subject to continued employment. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement for new employees joining X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR), un'azienda focalizzata sul miglioramento della vita delle persone affette da malattie rare del sistema immunitario, ha annunciato l'emissione di premi di inducimento ai nuovi dipendenti nell'ambito del suo Piano di Incentivazione Azionaria del 2019. I premi, approvati dal Comitato di Compensazione di X4, consistono in opzioni per l'acquisto di 744.468 azioni ordinarie di X4. Queste opzioni hanno un termine di dieci anni e un prezzo di esercizio di $0,6693 per azione, equivalente al prezzo di chiusura del 30 settembre 2024.
Le opzioni matureranno nell'arco di un periodo di quattro anni, con il 25% che matura dopo 12 mesi e il resto che matura mensilmente nei successivi 36 mesi, soggetto a un impiego continuato. Questi premi sono stati concessi in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per i nuovi dipendenti che si uniscono a X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR), una compañía enfocada en mejorar la vida de las personas con enfermedades raras del sistema inmunológico, ha anunciado la emisión de premios de inducimiento para nuevos empleados bajo su Plan de Incentivos de Acciones de Inducimiento de 2019. Los premios, aprobados por el Comité de Compensación de X4, consisten en opciones para comprar 744,468 acciones ordinarias de X4. Estas opciones tienen un plazo de diez años y un precio de ejercicio de $0.6693 por acción, igual al precio de cierre del 30 de septiembre de 2024.
Las opciones se consolidarán durante un período de cuatro años, con el 25% consolidándose después de 12 meses y el resto consolidándose mensualmente durante los siguientes 36 meses, sujetas a la continuación del empleo. Estos premios fueron otorgados de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) como un incentivo para los nuevos empleados que se unen a X4 Pharmaceuticals.
X4 제약 (Nasdaq: XFOR)은 희귀 면역계 질환을 가진 사람들의 삶을 개선하는 데 중점을 두고 있는 회사로, 2019 유인 주식 인센티브 플랜에 따라 새로운 직원에게 유인상 수여를 발표했습니다. 이 상은 X4의 보상 위원회에 의해 승인되었으며, X4의 보통주 744,468주를 구매할 수 있는 옵션으로 구성됩니다. 이 옵션은 10년의 기간을 가지며, 주당 $0.6693의 행사 가격을 가지고 있으며, 이는 2024년 9월 30일의 종가와 같습니다.
옵션은 4년 동안 분할 지급되며, 첫 12개월 후 25%가 확정되며, 나머지는 다음 36개월 동안 매달 확정됩니다. 이는 근무 지속에 따라 달라집니다. 이 상은 새로운 직원들에게 유인책으로 제공되었으며, Nasdaq 상장 규정 5635(c)(4)을 준수합니다.
X4 Pharmaceuticals (Nasdaq: XFOR), une entreprise axée sur l'amélioration de la vie des personnes atteintes de maladies rares du système immunitaire, a annoncé l'attribution de primes d'incitation à de nouveaux employés dans le cadre de son Plan d'Incentives en Actions de 2019. Les primes, approuvées par le Comité de Rémunération de X4, consistent en des options pour acheter 744,468 actions ordinaires de X4. Ces options ont une duree de dix ans et un prix d'exercice de 0,6693 $ par action, égal au prix de clôture du 30 septembre 2024.
Les options seront acquises sur une période de quatre ans, avec 25% acquises après 12 mois et le reste acquis mensuellement pendant les 36 mois suivants, sous réserve d'un emploi continu. Ces primes ont été attribuées conformément à la règle d'inscription Nasdaq 5635(c)(4) comme incitation pour les nouveaux employés rejoignant X4 Pharmaceuticals.
X4 Pharmaceuticals (Nasdaq: XFOR), ein Unternehmen, das sich auf die Verbesserung des Lebens von Menschen mit seltenen Immunsystemerkrankungen konzentriert, hat die Vergabe von Anreizprämien an neue Mitarbeiter im Rahmen seines Anreizaktionsplans von 2019 bekannt gegeben. Die Prämien, die vom Vergütungsausschuss von X4 genehmigt wurden, bestehen aus Optionen zum Kauf von 744.468 Aktien von X4. Diese Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 0,6693 $ pro Aktie, was dem Schlusskurs vom 30. September 2024 entspricht.
Die Optionen werden über einen Vierjahreszeitraum fällig, wobei 25% nach 12 Monaten fällig werden und der Rest monatlich über die folgenden 36 Monate fällig ist, vorbehaltlich einer Fortführung des Arbeitsverhältnisses. Diese Prämien wurden gemäß Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für neue Mitarbeiter, die zu X4 Pharmaceuticals stoßen, gewährt.
- Attraction of new talent through equity incentives
- Alignment of employee interests with company performance through stock options
- Potential dilution of existing shareholders' equity
BOSTON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 744,468 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares of X4 Pharmaceuticals (XFOR) were granted as inducement awards?
What is the exercise price of the inducement stock options granted by X4 Pharmaceuticals (XFOR)?
What is the vesting schedule for the inducement stock options granted by X4 Pharmaceuticals (XFOR)?
Under which plan were the inducement awards granted by X4 Pharmaceuticals (XFOR)?
